BiotechTube

ONO-2952 + Placebo comparator

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Irritable Bowel Syndrome (IBS)

Conditions

Irritable Bowel Syndrome (IBS)

Trial Timeline

Jun 1, 2013 → —

NCT ID
NCT01887002

About ONO-2952 + Placebo comparator

ONO-2952 + Placebo comparator is a phase 2 stage product being developed by Ono Pharmaceutical for Irritable Bowel Syndrome (IBS). The current trial status is terminated. This product is registered under clinical trial identifier NCT01887002. Target conditions include Irritable Bowel Syndrome (IBS).

What happened to similar drugs?

7 of 20 similar drugs in Irritable Bowel Syndrome (IBS) were approved

Approved (7) Terminated (1) Active (13)
✅Ramosetron + PlaceboAstellas PharmaApproved
✅Ramosetron + PlaceboAstellas PharmaApproved
✅duloxetineEli LillyApproved
✅Bacillus clausii + MetronidazoleSanofiApproved
✅Iberogast® and Iberogast® NBayerApproved
✅LinaclotideIronwood PharmaceuticalsApproved
✅Linaclotide + PlaceboIronwood PharmaceuticalsApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01887002Phase 2Terminated

Competing Products

20 competing products in Irritable Bowel Syndrome (IBS)

See all competitors
ProductCompanyStageHype Score
linaclotide + placeboAstellas PharmaPhase 2
35
YM060 + PlaceboAstellas PharmaPhase 3
40
Ramosetron + PlaceboAstellas PharmaApproved
43
Ramosetron + PlaceboAstellas PharmaApproved
43
YM060Astellas PharmaPhase 3
40
YM060 + placeboAstellas PharmaPhase 2
35
YM060Astellas PharmaPhase 3
40
linaclotide + PlaceboAstellas PharmaPhase 3
40
RamosetronAstellas PharmaPre-clinical
26
YM060Astellas PharmaPhase 2
35
ONO-2952 + ONO-2952 Matching PlaceboOno PharmaceuticalPhase 2
35
duloxetineEli LillyApproved
43
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)AbbViePhase 3
40
25mg Eluxadoline + 100mg EluxadolineAbbViePhase 3
47
Eluxadoline + PlaceboAbbViePhase 2
42
Placebo + LinaclotideAstraZenecaPhase 3
40
TegaserodNovartisPre-clinical
26
DNK333NovartisPhase 2
35
SMS995 + PlaceboNovartisPhase 1
29
DNK333 + PlaceboNovartisPhase 2
35